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Trends
There has been recent debate as to the
relative extents to which cellular trans-
membrane drug transports occur
through any phospholipid bilayer
region or is transporter-mediated only.
Much recent evidence suggests (per-
haps surprisingly) that phospholipid
bilayer diffusion is negligible.
A recent article in this journal sug-
gested that the expression proﬁle
and kinetics of known transporters
might not be adequate to explain the
most active drug ﬂuxes (of verapamil
and propranolol) in Caco-2 cells via
transporters only.
We show with our own simulations that
this is not in fact the case, especially
when evolutionary selection is taken
into account, and that the Haldane
relation accounts straightforwardly for
directional differences, even for equili-
brative transporters.
Typical protein transporters alone can
easily account for measured drug
ﬂuxes in Caco-2 cells.
1School of Computer Science
2Manchester Institute of
Biotechnology, The University of
Manchester, 131 Princess St,
Manchester M1 7DN, UK
3Centre for Synthetic Biology of Fine
and Speciality Chemicals
(SYNBIOCHEM), The University of
Manchester, 131, Princess St,
Manchester M1 7DN, United KingdomOpinion
Fitting Transporter Activities to
Cellular Drug Concentrations
and Fluxes: Why the
Bumblebee Can Fly
Pedro Mendes,1,2,3,4 Stephen G. Oliver,5,6 and
Douglas B. Kell2,3,7,*,@
A recent paper in this journal argued that reported expression levels, kcat and Km
for drug transporters could be used to estimate the likelihood that drug ﬂuxes
through Caco-2 cells could be accounted for solely by protein transporters. It
was in fact concluded that if ﬁve such transporters contributed ‘randomly’ they
could account for the ﬂux of the most permeable drug tested (verapamil) 35% of
the time. However, the values of permeability cited for verapamil were unusually
high; this and other drugs have much lower permeabilities. Even for the claimed
permeabilities, we found that a single ‘random’ transporter could account for the
ﬂux 42% of the time, and that two transporters can achieve 10  10S6 cmsS1
90% of the time. Parameter optimisation methods show that even a single
transporter can account for Caco-2 drug uptake of the most permeable drug.
Overall, the proposal that ‘phospholipid bilayer diffusion (of drugs) is negligible’
is not disproved by the calculations of ‘likely’ transporter-based ﬂuxes.
Pre-eminence of Transporter-Mediated Drug Uptake
For cases in which a drug must interact with one or more intracellular targets, and for all oral drugs, it
is necessary for drugs to cross at least one biomembrane. There is an increasing recognition that to
cross intact biological membranes drugs must or do hitchhike on transporters that are normally
involved with intermediary metabolism (e.g. [1–12]). It is therefore of interest to understand how the
use of speciﬁc inﬂux and efﬂux transporters translates into particular transmembrane ﬂuxes and
intracellular concentrations (and hence the biological effects of drugs and other solutes). A recent
example [13] brings the issue into sharp focus, where removing (genetically) just a single trans-
porter decreased the toxicity (and presumably accumulation) of the drug YM155 (sepantronium
bromide) by several hundred-fold. The implication of such data is that any ‘background’ rate
involving phospholipid bilayer diffusion must be rather less than 1%, or (as we have put it elsewhere
[9,10]) ‘phospholipid bilayer diffusion is negligible’. Another recent example (see Figure 2 in ref [14])
shows that metformin uptake can be accounted for entirely by four transporters. Indeed, this
essential lack of permeability in the absence of suitable transporters readily accounts for the failure
of drugs to penetrate to the sites where they are required. Anti-tuberculosis drugs provide another
important and (for patients) damaging example [15,16].
The nonlinear nature of many biochemical kinetics, and the complex behaviour of even simple
biochemical pathways, means that it is hard to ‘guess’ what might happen without seeking to
model it ﬁrst (e.g. [17–19]). Thus, a recent article in this journal [20] (and its subsequent710 Trends in Pharmacological Sciences, November 2015, Vol. 36, No. 11 http://dx.doi.org/10.1016/j.tips.2015.07.006
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Fig. 1. Relationships between Forward and Inverse Modelling. In forward (ODE-based) modelling, parameters such
as the network topology, enzyme concentrations, kcat and Km are the inputs and variables such as ﬂuxes and concentra-
tions are the output [18,19]. In inverse modelling the inputs are the variables such as ﬂuxes and concentrations, and one
must determine or estimate the parameters (and maybe even the network topology) that permits such variables to occur.supplementary iformation [21]) sought to carry out just such a modelling study, based on a series of
stated assumptions. The authors [20] also drew a major conclusion that (we consider) was at some
variance with the data presented. The two main purposes of the present paper are (i) to go through
their data and main argument, and, (ii) because natural evolution has at least one selection step, to
study what happens when instead of making assumptions solely about forward modelling, one
simply ﬁts the observables to appropriate models and their parameters (Figure 1).
A Note on the Word ‘Passive’ and Why One Should Use More Explicit
Alternatives
Despite our clear previous explanation of this term [9], Matsson and colleagues [20] (and many
other workers) continue to use the word ‘passive’ to mean two entirely different things (Figure 2).
The ﬁrst usage involves a thermodynamic statement only, and is best referred to as ‘equilibrative’
(‘passive’ transport is thermodynamically equilibrative; the ‘active’ version requires an input of
free energy and is then concentrative). We would stress that, as such, the word ‘passive’ has
nothing of itself to say about a mechanism of how a drug crosses a membrane. However,
‘passive’ transport is also far too often taken to mean ‘transport via bilayer lipoidal’ diffusion, a
perfectly acceptable intent provided this is made explicit, but one that is then best served by
calling it ‘bilayer lipoidal diffusion’ directly. Carrier-mediated diffusion may be active or passive in
the thermodynamic sense (and, for those purposes, is best referred to as either concentrative or
equilibrative). A very well-established term for the latter (carrier-mediated equilibrative transport)
is ‘facilitated diffusion’, while the term ‘active transport’ is perfectly adequate for concentrative
transporter-mediated solute inﬂux (or efﬂux). All of this therefore entirely avoids the ambiguity
common with the use of the term ‘passive’. We reiterate strongly that much trouble would be
avoided if the word ‘passive’ were dropped completely from all debates about transmembrane
drug uptake mechanisms. Conﬂating the two by showing its truth for one meaning (thermody-
namic) but then claiming that this thereby shows the other meaning of bilayer lipoidal is at best
unscientiﬁc. (Zheng and colleagues [22] illustrate this with an example in which bilayer transport
was not even measured directly as a dependent variable, and for a drug whose uptake is
stereoselective and hence necessarily transporter-mediated.)Trends in Pharmacological Sciences, November 2015, Vol. 36, No. 11 711
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Fig. 2. Two Orthogonal Aspects of Cellular Uptake in which the Word ‘Passive’ Is Sometimes (and
Unhelpfully) Used to Describe (and, in the Worst Cases, Conﬂate) Two Completely Different Concepts.
The ﬁrst is a thermodynamic usage meaning ‘equilibrative’, for which the antonym is ‘active’ or better ‘concentrative’. The
second usage is intended to be a mechanistic usage, and is sometimes taken to mean ‘via bilayer lipoidal bilayer diffusion’, in
which case it is best to state this. Carrier-mediated but equilibrative diffusion is historically referred to as ‘facilitated diffusion’.
Needless to say, showing that transport is equilibrative (or ‘passive’) does not explain whether its uptake is transporter-
mediated or otherwise. To avoid any such ambiguity, we suggest strongly that all workers simply avoid the word passive
entirely, and replace it with words that describe precisely and explicitly which of the two meanings (thermodynamic vs
mechanistic) is intended.Fluxes across Caco-2 Cell Membranes Explicable Via Transporter Reactions
Matsson and colleagues [20] proposed, as a model, the well-known Caco-2 cell system, and
sought to estimate how ‘likely’ it was, given the known expression proﬁles and kcat values of a
subset of transporters, whether or not they could reasonably be expected to account for the
ﬂuxes observed in the case of two drugs (propranolol and verapamil) with unusually high
permeabilities. At ﬁrst glance, this is an interesting idea. Note that Caco-2 cells are thought
(from transcriptomics or proteomics measurements) to express several hundred (e.g. [23–25]) of
the ca 450 catalogued SLC transporters, although (i) there is considerable variation in this
between laboratories [26], (ii) it is not known how reliable the expression proﬁling data are [26],
and (iii) it is recognised that ‘unknown’ transporters might be present. Thus, some of the authors
of [20] already published that there is an enormous expression level of an ‘HPT1’ human peptide
transporter [26,27] (indeed it is the highest expressed transporter in Caco-2 cells in each of the
10 laboratories participating in [26]), but such a transporter seems to make no appearance at all
in [20]. Thus, in the absence of any knowledge, nor of the inclusion of such highly expressed
transporters, these estimates are always likely to be underestimates. We entirely appreciate the
complexities of biological systems, and hence, the difﬁculty of reproducing the behaviour of even
the well-established Caco-2 system. However, to give an indication of the variance observable
within and between laboratories, Box 1 shows some of the data from precisely such a
comparison [26]. Obviously the variance between laboratories for the three drugs atenolol,
metoprolol and talinolol is at least an order of magnitude (sometimes more), with their median
values for A ! B being ca 0.5, 45 and 1.34  106 cms1.
Regarding the choice of drugs, Mattson and colleagues [20] state “Classical examples include
propranolol and verapamil. These have permeability coefﬁcients across Caco-2 intestinal
epithelial cell monolayers (the most commonly used cellular barrier for permeability studies)712 Trends in Pharmacological Sciences, November 2015, Vol. 36, No. 11
Box 1. Inter-Laboratory Comparison of Caco-2 Permeabilities
Data are replotted from Table 4 of [26] and illustrate that even within labs, and certainly between labs, there can be
variations of an order of magnitude or more in Caco-2 permeability measurements. The three drugs shown (atenolol,
metoprolol, talinolol) are encoded by shape, and the laboratories by the colour of the symbols. There were two separate
‘batches’ of Caco-2 cells tested (Figure I).
Inter-laboratory comparison of Caco-2 permeability
measurements for three drugs
(Hayeshi et al. Eur J Pharm Sci 35, 383–396)
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Figure I. Inter-Laboratory Comparison of Caco-2 Permeability Measurementsin the range 200–1000  106 cms1 [28,29].” Actually the rate published for R- or S-verapamil
in [28] was 100  106 cms1, and even decreased as concentrations exceeded 100 mM,
presumably because of substrate inhibition, with a similar value in [29]. Some of the authors of
Matsson et al. [20] in their reference 19 [30] published a value of 155  106 cms1, that for
propranolol in Artursson and Karlsson [31] was 41.9  106 cms1, in Camenisch et al. [32]kcat , km, and total protein expression values that
achieve a Papp of 1310.10–6 cm.s–1
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Figure 3. Variation of Parameters Necessary to Achieve a Flux of 1310  106 cms1 in an In Silico Caco-2
Transport System with a Single Transporter, Coloured by the Value of the Transporter Expression. The
equation and its units are given in Box 2.
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41.7  106 cms1, van Breemen and Li [33] gave 50  106 cms1, while that for propranolol
in Figure 3 of [29] was 700  106 cms1, but no matter. Corti and colleagues [34] (their
Table 2) give 41.9, 106 cms1 for propranolol and 15.8  106 cms1 for verapamil. This said,
the ‘observable’ rates stated in Figure 3A(i) of [20] as 1310  106 cm1 for verapamil and
230.106 cm1 for propranolol come from Table 3 of a paper by Avdeef [29] (P. Matsson,
personal communication), and are obviously at some variance with these other numbers. (They
are based on a very rapid stirring – 700 rpm – that does not occur adjacent to natural epithelia.)
Anyway, although these high values are close to being complete outliers (Table 1), we shall take
the larger numbers as given, and the question arises as to whether typical ﬂuxes of individual
carriers can come close to being able to achieve these overall values of Papp.
The authors [20] (and most of the data have subsequently been made available as Supplemen-
tary Information [21]), took random samples of individual transporters whose kcat values (for just
18 transporters using unstated substrates), Km and expression levels were drawn from a
random distribution of a known subset. Note the wide variation for each one – in Figure 2B
of [20] the kcat value for VMAT2 varied 200-fold). They found [20] that that the observed rates for
verapamil and propranolol at 50 mM were reached in 7% and 18% of cases, and that if it is was
assumed that ﬁve transporters might be involved equally then this would be found for 35% of
cases for verapamil (and presumably a signiﬁcantly greater percentage for propranolol, though
that was not stated). Presumably these drugs were chosen because of their high ﬂuxes, albeit
that their uptake shows enantioselectivity (e.g. [35,36]) and thus must be transporter-mediated,
so this is very far from making this an ‘unlikely’ event. Thus, even though we consider this to be
entirely the wrong strategy, this seems to us to be a rather positive endorsement of the fact that
most ﬂux is perfectly capable of going via transporters even for drugs that were apparently
chosen to have the highest total rates. Matsson et al. [20] also comment that “marketed drugs
target between one and eight distinct proteins (5th to 95th percentile range [37])”. Actually, on
average each marketed drug has six known targets [38], so we may assume this is something of
an underestimate. In the case of verapamil, it is transported by multiple isoforms of SLC22 [39–
41] among others yet uncharacterised [42,43], as is propranolol [44,45], so the calculations
presented by Matsson and colleagues are necessarily likely to underestimate the transporter-
mediated ﬂuxes. As we have said before [6,9], absence of evidence is not evidence of absence. It
is also worth commenting that, in the absence of other knowledge, the absolute transcript level
alone can be an adequate surrogate for predicting ﬂuxes in genome-wide studies [46].
However, natural (Darwinian) evolution has a selection step in it, and it is precisely this that
accounts for the fact that complex organisms evolve, however ‘unlikely’ or ‘implausible’ that may
be [47–49]. Thus, from our perspective, the correct strategy is to start with the data and ﬁnd the
parameter values that can ﬁt it for one or more transporters, and how often such a ﬁt can be
obtained [17,50]. This was performed 1000 times, and on each occasion, with just a single
transporter, we could, within the bounds of the parameters given by Matsson and colleagues,
achieve a ﬂux of 1310  106 cms1 on every single occasion. We therefore did not repeat the
analysis with more than one transporter. The data are given in Figure 3. Two features are of note.
First, and fairly obviously, is the fact that a given Vmax can be obtained from varying the coupled
values of kcat and transporter concentration. Secondly, although they represent different aspects
of enzyme action [51], the values for Vmax and Km are not actually completely independent of
each other under selection. This is in fact related to the Haldane relationship discussed below.
Permeabilities of Other Drugs
A table of various substances’ permeability coefﬁcients in Caco-2 cells is given in Table 1 of [30]
(and stated to have been redrawn in Figure 2A of [52], though the former has 23 and the latter 31
data points). (Note that Bergström and colleagues [30] also avoided unstirred layer effects, albeit
that they anyway have equal (ir)relevance to measurements of ﬂuxes and the transporter kinetics714 Trends in Pharmacological Sciences, November 2015, Vol. 36, No. 11
Table 1. A Comparison of the Values of Caco-2 Permeability Chosen for Verapamil and Propranolol by [20]
(and Taken from [29]) with Those Given in Various Other Papers
Compound 106  Caco-2 Papp (cms1) Reference
verapamil 1310 [20,29]
155 [30]
15.8 [34]
26.3 [32]
9.8 [82]
45.7 [83]
12.4 [84]
152 [85]
62.4 [86]
69.4 [87]
22 [88]
22–24 [89]
9 [90]
25 [91]
22 [92]
propranolol 230 [20,29]
41.9 [34]
50 [33]
27.5 [60]
29.2 [64]
25.8 [64]
44.6 [64]
39.8 [64]
57 [64]
59.7 [64]
30.1 [61]
41.7 [32]
17.5 [82]
26.3 [63]
39.8 [83]
12.9 [84]
27 [93]
8–16 [35]
35.3 [94]
21.8 [62]
27.5 [87]
11.1–27.7 [95]
16 [88]
21–36 [89]
8.2 [96]
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Figure 4. Some Values of Caco-2 Permeability of Various Drugs and Their Relative Independence from Log P.
Data are replotted from Table 1 of [30].with which they are supposed to be comparing.) We have plotted out those data (Figure 4), from
which at least three conclusions are evident: (i) the Papp for very few of the compounds exceeds
even 100  106 cms1, and of the only two that exceed 200  106 cms1, one (ethinyl estradiol)
is a sterol that is heavily metabolised to its sulphate and is transported by the sterol transporter
SLC51 [53,54]) and (as the sulphate) by a series of anion transporters [55–57], while the other
(phenazopyridine) is a rarely used local anaesthetic (and adenine analogue) that, in fact, is seen as
poorly transported/metabolised (class IV) in the BDDCS system [58]; (ii) there is no discernibly linear
relationship between permeability and the log of the octanol:water partition coefﬁcient (see also
[1,9]) (that we have purposely plotted on the ordinate to highlight the fact that it is not an
independent variable), (iii) as previously pointed out [4,6,9] almost all of them do have known
transporters. While the contributions of paracellular and efﬂux transporters is not known (and
verapamil is a well known P-gp inhibitor, e.g. [59]), similar conclusions on the normally rather lower
values for Caco-2 permeability may be drawn from the compilations of Artursson & Karlsson [31]
(20 drugs, highest permeability 54.5  106 cms1), Corti et al. [34] (21 drugs, highest permeability
83  106 cms1), Yee [60] (26 drugs, highest permeability 71  106 cms1), Camenisch et al.
[32] (25 drugs, highest permeability 61.7  106 cms1), Pade & Stavchansky [61] (9 drugs,
highest permeability 45.5  106 cms1), Yazdanian et al. [62] (51 drugs, highest permeability
36.6  106 cms1), Hou et al. [63] (77 drugs, highest permeability 52.5  106 cms1), Uchida
et al. [64] (8 drugs, highest permeability 55.3  106 cms1), and Lozoya-Agullo et al. (2015) [65]
(15 drugs, highest permeability 41.8  106 cms1). The median permeability of the drugs listed in
the cited references is less than 20  106 cms1, which is considerably lower than the kinds of
numbers given above and highlighted in [20].
As described in Box 2 and the supplementary information, we have also used COPASI to model
this system using 10,000 values of Km, kcat and protein expression drawn from the best-ﬁt log-
normal distribution given in the supplementary data [21] of [20]. A number of points follow from
this Figure: (i) there is a tendency for a particular transporter to dominate, i.e. there is a law of
diminishing returns, (ii) in our hands, we could achieve the ‘target’ ﬂux of 1310  106 cms1 for716 Trends in Pharmacological Sciences, November 2015, Vol. 36, No. 11
Box 2. Materials and Methods and Relevant Calculations
As described in the supplementary material of Matsson et al. [20], an apparent permeability, Papp, can be calculated from
the ﬂux of a drug passing through one or several transporters. First the steady state ﬂux, Ji, at which the drug passes
through each transporter is calculated using the Henri-Michaelis-Menten equation, given: the concentration of the drug
([D]), the concentration of the transporter ([Ti]0), the area (A), the area density of proteins in the membrane
(a = 0.5 mgcm2), the turnover number kcat,i, and the Michaelis constant Km,i. The sum of the steady-state ﬂuxes (Jtot)
through all the transporters is then the total steady-state ﬂux of drug entry:
Jtot ¼
X
i
Ji ¼
X
i
½Ti0Aakcat;i½D
Km;i þ ½D (1)
That steady-state ﬂux of drug entry would correspond to a certain apparent permeability (Papp) through the following
equation:
Papp ¼ Jtot
A ½D1000
¼ Jtot1000
A½D ; (2)
where A is the area of the membrane in the permeability assay, taken as 0.33 cm2 (Matsson, personal communication).
The factor 1000 converts the concentration of the drug ([D]) from pmolL1 to pmolcm3. We constructed a kinetic
model in the software COPASI [97] version 4.15ii that incorporates Eqs (1) and (2) and supply this model as supple-
mentary data in the SBML format [98]. We then used this model to a) ﬁnd many sets of parameter values that lead to rates
of entry through a single transporter equivalent to the permeability of verapamil, and b) generate 10,000 models with
those parameters sampled randomly from appropriate distributions (see supplementary data) with 1, 2 and 5 trans-
porters. We provide COPASI native ﬁles for both a) and b) in the supplement.
It is, as usual, necessary that all numbers entered in Eqs (1) and (2) be in compatible (i.e. self-consistent) units. Thus to
make this process more transparent, we converted all data in the supplementary material of Matsson et al. [20] to
compatible units as follows:
 transporter concentrations ([Ti]0): pmolmg1 total protein;
 drug concentrations ([D]: pmolL1
 area (A): cm2
 protein area density: mgcm2
 turnover numbers (kcat,i): s1
 Michaelis constant (Km,i): pmolL1
 ﬂuxes (Jtot and Ji): pmols1
 apparent permeability (Papp): cms1verapamil with just a single transporter on more than 12% of the occasions (Figure 5), and for 2,
3, 4 and 5 transporters the percentage successes were 23%, 35%, 45% and 54% (the latter
marked on the Figure), (iii) for propranolol the success with 5 transporters was 80% and, for a
more typical value for Papp of 10.10
6 cms1, we could achieve this in 90% of simulations for 5
transporters (Figure 5). (An entirely separate simulation in R – not shown – led to the same
conclusion.)
Given that entirely reasonable expectations of transporter expression proﬁles can thus easily
account for the ﬂuxes of even the most rapidly permeable drugs, and even more so for the vast
majority of other less permeable drugs, we see no need to invoke bilayer lipoidal permeation at
all. In many cases, the transporters involved in Caco-2 transport are entirely well established and
leave no room for bilayer lipoidal diffusion. Of course the fact that most drugs have nothing like
those large permeabilities means that it is even easier to explain their permeabilities even in terms
of ‘random’ expression levels, Km and kcat values (Figure 5).
Explicability of a Solely Transporter-Mediated Flux of Some Other Drugs
We noted above the fact [13] that much more than 99% of the transport of sepantronium
bromide (YM155) could be shown to pass through a single transporter (SLC35F2), and have
stressed [9] that a straightforward way of estimating this is to vary the expression levels of known
transporter enzymes. Thus, Chu and colleagues [66] varied the expression level of the PepT1
(SLC15A1) transporter in Caco-2 cells and looked at the effect of this on the transport of
cephalexin. We have replotted those data in Figure 6, where it is obvious that, within experi-
mental error, the background rate in the absence of SLC15A1 is indistinguishable from zero. ToTrends in Pharmacological Sciences, November 2015, Vol. 36, No. 11 717
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Figure 5. Rank Order of Papp Obtained when Parameters were Varied for 1,2,3,4 and 5 Transporters, with
Km = 50 mM, as in Fig. 3. A Papp of 1310  106 cms1 is achieved in 12% of cases for 1 transporter and 54% of cases
for 5 transporters, with correspondingly more frequent successes when Papp is lower.interpret this, we can do little better than quote the original: “In Caco-2/hPEPT1 cells, an
excellent correlation was observed between cephalexin uptake and hPEPT1 expression
(R2 = 0.96, P < 0.005). This demonstrates that cephalexin uptake is directly proportional to
hPEPT1 expression” [66].
So, to be clear, even with the most extreme assumptions (most permeable drugs, not recog-
nising all the transporters and their multiple isoforms, no selection for kcat, independence from
each other of individual transporter expression proﬁles, kcat and Km, etc.) most of the time one
can in fact easily account for Papp, simply on the basis of the arguments and data presented [20],
for a fully transporter-mediated transport of drugs. There is consequently no need to invoke
lipoidal bilayer diffusion at all.
Two Irrelevancies on which We Have Nothing Discriminating to Say
Matsson et al. [20] also make much of two other features: (i) a statement (no actual data are
shown) that transport rates are ‘linear’ with substrate concentrations over wide ranges, and that
this supposedly cannot be explained by combinations of transporters, and (ii) that equality of
transport rates in two directions is hard for transporter-only theories to explain. Regarding (i), we
have previously pointed out [6,9] that, especially in the absence of any knowledge of the
transporters involved nor their detailed enzyme kinetics, linearity or its lack is not a criterion
of anything (similarly, on the other side, we do not seek to claim that saturation ‘proves’
transporter involvement). Regarding (ii) we have also previously pointed out [6] that, for equi-
librative transporters performing facilitated diffusion, this is a simple thermodynamic conse-
quence of the Haldane relation (of enzyme kinetics, that can be read in any suitable textbook718 Trends in Pharmacological Sciences, November 2015, Vol. 36, No. 11
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Fig. 6. Cephalexin Uptake is Directly Proportional to hPEPT1 Expression. Data are replotted from [66] and show,
to a good approximation by varying the transporter expression level, that the ‘background’ uptake rate of cephalexin is
negligible.such as [67–69]). Speciﬁcally, the Haldane relation states that (Vm,f  Km,r)/(Vm,r  Km,f) = Keq.
Not only do transporters explain this bidirectional equivalence of ﬂuxes straightforwardly but it is
a necessary fact for enzymes or transporters where Keq = 1. Put another way, for a given
external substrate concentration, instantaneous ﬂuxes can differ between the two directions in a
Caco-2 set-up even when Keq = 1 (i.e. transport is equilibrative), simply because Km and Vmax
(kcat) values can be whatever they are, subject to the constraint of the Haldane relationship.
Matsson et al. [20] state “equilibrative transporters (which mediate substrate ﬂux along con-
centration gradients; {their} Box 1) can – under certain circumstances – give rise to direction-
independent rates. Thus, near-unity ﬂux ratios do not unambiguously exclude transporter
involvement”. Indeed they do not, as when measurements are performed properly (a recent
example of near-unity ratios is [70]) they directly reﬂect the Haldane relationship. Possibly a failure
to understand this principle follows from the conﬂation of two meanings of the word ‘passive’,
but we do hope that this particular line of reasoning can be cast properly in the context of the
Haldane relationship, which is where it belongs.
What Criteria Should One Use to Assess the Role of Transporters in Drug
Uptake?
We have previously set down why some criteria raised in this debate about the mechanisms of
transmembrane drug transport are simply non-discriminatory. We gave two above and others
elsewhere [9]. These are not therefore of interest. Much more important is a general strategy
used throughout modern molecular genetics to determine the involvement of a gene (product) in
a process. This is to vary the expression of the gene product as an independent variable
(whether as a knockdown or via a regulatable promoter such as tetO [71]), and to observe the
effects of that on the dependent process of interest (such as uptake transport). We already gave
many hundreds of examples [1]. Similar comments apply to the role of the Henle-Koch
postulates in microbiology (e.g. [72,73]).Trends in Pharmacological Sciences, November 2015, Vol. 36, No. 11 719
Outstanding Questions
What are the quantitative expression
proﬁles of endogenous metabolite
transporters (that are also responsible
for transporting drugs) between differ-
ent tissues?
Are these transporters equilibrative or
concentrative, and if concentrative
what is their mechanism of energy
coupling?
What is the detailed enzymology of
these transporters, and what are their
quantitative structure-activity relation-
ships (QSARs),
How do these vary between different
cells, tissues, organisms and species?
How do the uptake proﬁles between
different cells of particular drugs covary
with the expression proﬁles of particu-
lar drug transporters, and how might
we use these (with the QSARs) to pre-
dict the distributions of any drug?
Can we vary the expression proﬁles (by
nutritional, pharmacological or other
means) to target speciﬁc drugs to spe-
ciﬁc tissues?However, Mattson et al. state “At ﬁrst glance, the transporters only model may appear
impossible (or at least extremely daunting) to test: to exhaustively conﬁrm the hypothesis,
one would need to identify the missing carriers for all transported drug molecules”. Not at all, and
it is no more daunting than seeking the genes (and their products) that are responsible for any
biological process of interest. Certainly the ﬁrst step in any systems biology model is qualitative –
to identify the players [7,8,18,19]. However, when one has identiﬁed them, it is easy to assess
their contributions, and we gave examples above (such as that for cephalexin in Figure 6). Indeed
Matsson et al. [20] later comment “One avenue to identify such novel (sic) drug transporters
would be the use of genome-wide single-gene knockout libraries in model organisms like
Saccharomyces cerevisiae, CRISPR–Cas9 knock-out libraries in human cells, or human haploid
genetic screens. Oddly enough this is precisely what we have previously stressed [9], and what
we [11] already did (though these papers were not cited by Matsson et al. [20]). Others have
adopted a similar and highly effective strategy (e.g. [13]) showing extremely clearly that when the
pertinent transporters are removed the background uptake (or toxicity of a cytotoxic drug) is
negligible. What we now need are QSAR models for each of the main transporter families, to
incorporate into the digitally available human metabolic network [8,74,75].
Other Evidence That Protein Carrier-Mediated Transport Is the Dominant
Means of Transembrane Uptake of Pharmaceutical Drugs
As we have stressed before (e.g. [6,9,10,76]), and we do not repeat the references here, there is
considerable evidence for a requirement for transporters for the transmembrane transport of even
very small and often hydrophobic molecules. These include alkanes, fatty acids, gases such as
CO2, O2 and NO, ammonia, glycerol and so on, so the bilayer lipoidal permeability in real biological
membranes must necessarily be very small. This also provides a ready explanation for a variety of
features that are not easily explained (at least without extra ad hoc hypotheses) by a view that has it
that much or most of the cellular uptake of pharmaceutical drugs occurs through the phospholipid
bilayer. Indeed, given that the effect of changing lipids in biophysical terms is not seen as that great,
any heterogeneity of uptake between cells, tissues and organisms is most simply explained in
terms of the varying expression of the relevant transporters [4,6,9,10]. Imaging mass spectrometry
(e.g. [77–79] is beginning to provide outstanding data on the very considerably extent of hetero-
geneity of drug transport and distribution, while the human proteome atlas [80] and comparable
transcriptome data [81] show the equivalent heterogeneity of transporters and other proteins.
Concluding Remarks
In conclusion (and see also the Outstanding Questions box), the test proposed [20] to see if a
random selection from a nominally known distribution of properties of known transporters is a
nice idea. Despite the opposite interpretation taken [20], however, the forward modelling data do
indeed show that transporters can easily account for the uptake of even the most permeable
drugs, even when their permeabilities are given as being several times greater than those of other
comparable measurements. This is even more the case for all the other drugs that naturally have
considerably lower experimental permeabilities. Parameter estimation data based on selection
show it even more clearly. In a similar vein, and famously (if apocryphallyi), it was suggested that
physics-based calculations implied that the bumblebee could not ﬂy. Happily the bumblebees
were selected by evolution so that they could, just as transporters were selected to be able to
sustain the necessary transport ﬂuxes.
Note Added in Proof
A recent major review stresses the importance of the issues discussed in [99].
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